In a new study, researchers have found a new treatment option for heart disease in patients with diabetes.
They reported that an FDA-approved drug used to treat chronic heart failure improves heart function in diabetes.
The research was conducted by a team from Nanjing First Hospital in China.
The term diabetes mellitus is used to denote diseases that alter how the body uses sugars, specifically glucose.
Glucose is the main source of energy for the brain and an important energy source for all cells in the body. Eventually, all types of diabetes lead to excess glucose in the blood.
Over time, high blood glucose levels cause serious health problems, including damage to blood vessels and nerves that control the heart.
Heart disease, diabetic cardiomyopathy (DCM), is a common cause of death in patients with diabetes.
LCZ696 is FDA-approved for the treatment of patients with chronic heart failure. However, the role of LCZ696 in DCM has not been determined.
In the current study, the team examined the effects of LCZ696 treatment in diabetic mice.
They found LCZ696 could reduce apoptosis (cell death), inflammation, oxidative stress, cardiac remodeling, and cardiac dysfunction.
LCZ696 treatment also reduced inflammation in high-glucose conditions.
These results show that LCZ696 could help treat diabetes by reducing inflammation, oxidative stress, and apoptosis.
LCZ696 is considered to be one of the most important clinical breakthroughs in the field of cardiology over the past 10 years.
The new study will provide new therapeutic ideas for the treatment of diabetic heart disease.
The lead author of the study is Dr. ZuoYing Hu in the Department of Cardiology at Nanjing First Hospital.
The study is published in Experimental Biology and Medicine.
Copyright © 2019 Knowridge Science Report. All rights reserved.
